EyePoint Pharmaceuticals (STU:PV3B) Accumulated other comprehensive income (loss) : €0.85 Mil (As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is EyePoint Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. EyePoint Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was €0.85 Mil.

EyePoint Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) declined from Sep. 2024 (€1.06 Mil) to Dec. 2024 (€0.98 Mil) and declined from Dec. 2024 (€0.98 Mil) to Mar. 2025 (€0.85 Mil).

EyePoint Pharmaceuticals's annual Accumulated other comprehensive income (loss) increased from Dec. 2022 (€0.74 Mil) to Dec. 2023 (€0.79 Mil) and increased from Dec. 2023 (€0.79 Mil) to Dec. 2024 (€0.98 Mil).

EyePoint Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for EyePoint Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Accumulated other comprehensive income (loss) Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

0.69

0.74

0.79

0.98

EyePoint Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															0.77	0.74	1.06	0.98	0.85

EyePoint Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

EyePoint Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

EYPT:USA PV3B:Germany

Address

480 Pleasant Street, Suite A-210, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals Headlines

No Headlines